Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
NCT ID: NCT03315364
Last Updated: 2024-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
549 participants
INTERVENTIONAL
2017-12-18
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
NCT01684215
RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
NCT06481553
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer
NCT04332549
A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer
NCT00915369
Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
NCT00356811
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
* Multicenter, Open-label, Single arm, Simon's optimal two-stage design
2. Phase III clinical trial
* Multicenter, Prospective Randomized Open-label Blinded Endpoint (PROBE) design
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liporaxel® (oral paclitaxel)
* 28 days (4 weeks) will be set as one cycle of administration and Liporaxel® will be administered for 3 weeks, twice a day, every morning and evening (D1, D8, D15) and will take a week off on 4th week.
* Liproaxel® 200mg/m2 will be orally administered twice a day (morning, evening) 1 hour after meal for D1, D8, D15 of every cycle. 10 hour-interval is recommended for between each administration.
Oral paclitaxel
Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Taxol® (IV paclitaxel)
* 28 days (4 weeks) will be set as one cycle and for every 3 week administration, 1 week off dose period will be given.
* Taxol® 80mg/m2 will be administered via IV and it must be diluted before drip administration. Dilute with 0.9% sodium chloride injection solution to make final concentration of 0.3-1.2 mg/mL.
Paclitaxel injection
Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral paclitaxel
Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Paclitaxel injection
Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* Measurable disease (revised RECIST, version 1.1).
* Hormone receptor (ER/PR) positive or negative, HER2 negative.
* Subjects were eligible for the study regardless of their previous lines of endocrine therapy.
* No prior chemotherapy is allowed in metastatic disease.
* Subjects who administrated the last dose of taxane class drug ≥12months ago as from the first administration day.
* ECOG performance status ≤1.
* Neuropathy grade \<2.
* Subjects with central nervous system metastasis should be excluded.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daehwa Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sung-bae Kim, M.D., Ph.D
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oncology Complex Center - Burgas'' Ltd., Medical Oncology Department
Burgas, , Bulgaria
Multi-profile Hospital for Active Treatment Uni Hospital Ltd. Medical Oncology Department
Panagyurishte, , Bulgaria
Medical Center Nadezhda Clinical" Ltd.,
Sofia, , Bulgaria
Anhui Cancer Hospital
Hefei, Anhui, China
Cancer Hospital Chinese Academy Of Medical Sciences
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
The First Affiliated Hospital Of Hainan Medical College
Haikou, Hainan, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Tianjin Cancer Hospital
Zhengzhou, Henan, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
First Affiliated Hospital of Jilin University
Changchun, Jilin, China
Liaoning Cancer Hospital
Shenyang, Liaoning, China
Shangdong Cancer Hospital
Jinan, Shandong, China
Linyi Cancer Hospital
Linyi, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
The First Affiliated Hospital of Xi'an Jiaotong university
Xi’an, Shanxi, China
West China School Of Medicine Sichuan University
Chengdu, Sichuan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Zhejiang University School Of Medicine Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
Henan Cancer Hospital
Zhengzhou, , China
Tolna County Balassa János Hospital
Szekszárd, , Hungary
Szent Borbála Hospital
Tatabánya, , Hungary
Institute for Oncology and Radiology of Serbia
Belgrade, , Serbia
Clinical Hospital Center Bežanijska Kosa, Department of Oncology
Belgrade, , Serbia
Oncology Institute of Vojvodina
Kamenitz, , Serbia
Health Center Kladovo, Oncology Department
Kladovo, , Serbia
Clinical Center Kragujevac Center of Oncology and Radiotherapy
Kragujevac, , Serbia
General Hospital Krusevac, Outpatient Clinic for chemotherapy
Kruševac, , Serbia
Clinical Center Niš, Clinic for Oncology
Niš, , Serbia
Wonju Severance Christian Hospital
Wŏnju, Gangwon-do, South Korea
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Cha University Cha Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
Inje University Haeundae Paik Hospital
Busan, , South Korea
Kosin University Gospel Hospital
Busan, , South Korea
Pusan National University Yangsan Hospital
Busan, , South Korea
Keimyung University Dongsan Medical Center
Daegu, , South Korea
Konyang University Hospital
Daejeon, , South Korea
Gang Neung Asan Hospital
Gangneung, , South Korea
Gachon University Gil Medical Center
Incheon, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Yonsei University Severance Hospital
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Catholic University of Korea Seoul ST. Mary's Hospital
Seoul, , South Korea
Gangnam Severance Hospital
Seoul, , South Korea
Uijeongbu ST. Mary's Hospital
Uijeongbu-si, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kim SB, Seo JH, Ahn JH, Kim TY, Kang SY, Sohn J, Yang Y, Park KH, Moon YW, Lim S, Kang MJ, Yoon KE, Cho HJ, Lee KS. Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). Ther Adv Med Oncol. 2021 Dec 15;13:17588359211061989. doi: 10.1177/17588359211061989. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
107CS-5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.